Compositions and methods for treating and diagnosing chemotherapy-resistant cancers

A chemotherapeutic, cancer-based technique applied in the field of identifying patients with chemotherapy-resistant cancers, addressing issues such as poor tumor understanding

Inactive Publication Date: 2017-08-29
F HOFFMANN LA ROCHE & CO AG
View PDF35 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the key regulators of reactive stroma and the specific mechanisms by which reactive stroma affects tumor progression, therapy response, and clinical outcome in EOC are poorly understood

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods for treating and diagnosing chemotherapy-resistant cancers
  • Compositions and methods for treating and diagnosing chemotherapy-resistant cancers
  • Compositions and methods for treating and diagnosing chemotherapy-resistant cancers

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0198] Example 1: Identification of a "reactive stroma" gene signature upregulated in initial chemotherapy-resistant ovarian tumors

[0199] To identify molecular features associated with initial chemotherapy resistance in EOC, a panel of high-grade serous or endometrioid ovarian tumors with a clinically well-defined response to initial chemotherapy was selected (Table 6). This discovery set consisted of tumor specimens from 32 patients with initial chemotherapy resistance and 26 patients with initial chemotherapy sensitivity. All patients were treated with a combination of platinum and taxane as first-line chemotherapy. Initial chemotherapy-resistant patients were selected based on already having disease recurrence or progression within 6 months of completion of platinum-based first-line chemotherapy, and chemotherapy-sensitive patients were selected based on not having had recurrence or progression within 12 months of initial chemotherapy patient. Twenty-seven of the 32 ch...

Embodiment 2

[0212] Example 2: Specific derivation and modulation of reactive stromal signature genes in tumor-associated fibroblasts

[0213] To determine which specific cell types express reactive stromal signature genes, POSTN and FAP RNA ISH analyzes were performed on whole slides of tumor specimens from the entire cohort of 85 tumor specimens. Additionally, POSTN and FAP IHC, and LOX RNA ISH analysis were also performed on 15 representative tumor specimens. Representative images of ISH and IHC showing these markers are shown in Figure 3A. In Plat-S primary tumors, none or significantly lower levels of reactive stromal signature genes were detected in stromal or tumor cells by ISH or IHC. In contrast, in Plat-R primary and recurrent tumors, POSTN was found to be expressed only in tumor-associated fibroblasts, whereas LOX was mainly expressed in tumor-associated fibroblasts and at a lower level in tumor cells and FAP. Tumor-associated fibroblasts expressing POSTN / LOX / FAP also showed ...

Embodiment 3

[0214] Example 3: stromal expression of POSTN is associated with a desmogenetic phenotype

[0215] Desmogenesis is a common pathological phenotype found in many cancer types. Histologic manifestations of desmogenesis include marked overproduction of extracellular matrix proteins, and extensive proliferation and disintegration of myofibroblast-like cells. Changes in stromal cell proliferation and deposition of extracellular matrix components lead to marked changes in overall tissue heterogeneity and elasticity, with concomitant interstitial fluid pressure. These changes have been suggested to contribute to chemotherapy resistance in cancer. To assess the potential link between reactive matrix molecular signatures and physiological features of desmogenesis, the degree of desmogenesis was scored on H&E-stained whole-tissue sections of the entire cohort of tumor specimens in this study. Of the 85 specimens scored, 26 of them were considered too difficult to score due to tissue d...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides methods of using expression levels of one or more stroma signature genes as selection criteria for determining a patient with cancer that is chemotherapy-resistant who may benefit from a particular anti-cancer therapy, such as stroma-targeted therapy, anti-angiogenic therapy, and / or immunotherapy. The present invention also provides methods of using expression levels of one or more stroma signature genes as a selection criterion for treating cancer patients, such as ovarian cancer patients, with a stroma-targeted agent.

Description

[0001] sequence listing [0002] This application contains a Sequence Listing which has been filed electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on December 22, 2015, is named 50474_092WO3_Sequence_Listing_12_22_15_ST25 and is 4552 bytes in size. field of invention [0003] The present invention relates to methods for identifying patients with chemotherapy-resistant cancers. Background of the invention [0004] Epithelial ovarian cancer (EOC) is the leading cause of death from gynecologic malignancies, and the treatment of EOC continues to present considerable clinical challenges. The current standard of care for EOC consists of aggressive surgical cytoreduction followed by platinum-based and taxane-based adjuvant chemotherapy. Although the response rate to this treatment is high, 20-30% of cases are resistant and progress during or within 6 months of completion of primary therapy. As such, resistant cance...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/68A61K39/395A61P35/00A61K33/243
CPCA61K39/3955C12Q1/6886C12Q2600/106C12Q2600/158A61K33/243A61K38/212A61P1/00A61P11/00A61P13/12A61P15/00A61P15/02A61P25/00A61P35/00A61K31/337C12Q1/6806G01N33/57449A61K31/4745A61K31/495A61K31/7068A61K45/06C07K16/18C07K16/22C07K2317/24C12Q2600/112
Inventor Y·王
Owner F HOFFMANN LA ROCHE & CO AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap